Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice

  title={Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice},
  author={Yan Zhou and Xiao Leng and Hua Li and Shu-xia Yang and Tai Yang and Limei Li and Ying Xiong and Qiang Zou and Yang Liu and Yantang Wang},
  journal={Molecular Medicine},
BD750, a novel JAK3/STAT5 inhibitor, can inhibit T cell proliferation. This study aims to evaluate whether BD750 can induce tolerogenic dendritic cells (tolDC) and their function in experimental autoimmune encephalitis (EAE) in mice. Following BD750 treatment, lipopolysaccharide (LPS)-induced maturation of DCs, allogeneic T cell proliferation, Th1 and Th17 cell functional differentiation, and STAT5 and AKT activation were determined. The effect of tolDC loaded with antigen peptide on the… Expand
Regulatory Dendritic Cells Induced by K313 Display Anti-Inflammatory Properties and Ameliorate Experimental Autoimmune Encephalitis in Mice
K313-modified DCregs show anti-inflammatory properties in vitro and have a significant positive effect on the EAE disease in vivo, indicating that K313-inducedDCregs pulsed with auto-antigen might have potential use as a therapeutic approach for autoimmune inflammation of the central nervous system. Expand
Diazepam Impairs Innate and Adaptive Immune Responses and Ameliorates Experimental Autoimmune Encephalomyelitis
Results indicate that DZ is a potent immunomodulator capable of controlling undesired innate and adaptive immune responses, both at the beginning of these responses and also once they have started. Expand
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA
Electroporation with mRNA is an efficient and versatile tool to generate myelin-presenting tolDC that are capable to stabilize the clinical score in EAE, and these results pave the way for further research into mRNA-electroporated tol DC treatment as a patient-tailored therapy for MS. Expand
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Expand
Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy
Three main areas of active research in immune tolerance are focused on, tolerogenic vaccines aiming at robust, lasting autoantigen-specific immune tolerance, T cell therapies using Tregs to establish active dominant immune tolerance or T cells (engineered to express chimeric antigen receptors) to delete pathogenic immune cells. Expand
Donor-Specific Regulatory T Cell-Mediated Immune Tolerance in an Intrahepatic Murine Allogeneic Islet Transplantation Model with Short-Term Anti-CD154 mAb Single Treatment
It is demonstrated for the first time that a short-term anti-CD154 mAb single treatment could induce FoxP3+ Treg cell-mediated immune tolerance in the intrahepatic murine allogeneic islet transplantation model. Expand
Chemical composition of Erycibe schmidtii and antiproliferative activity of scopoletin on immature dendritic cells
Scopoletin functionally reduced proliferation level of bone marrow immature dendritic cells (BM-iDCs) more than 50%, relative to vehicle, however, scopo letin exhibited no effect on the phagocytosis or survival of BM- iDCs in vitro. Expand


Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance
The results revealed that tofacitinib-treated DCs maintained a steady semimature phenotype with a low level of proinflammatory cytokines and costimulatory molecules, and the antigen-specific tolDCs may represent a new avenue of research for the development of future clinical treatments for MS. Expand
Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses.
Treatment with type II collagen-pulsed tolerogenic DCs decreases the proportion of Th17 cells in arthritic mice and simultaneously reduces the severity and progression of arthritis. Expand
Midkine Inhibits Inducible Regulatory T Cell Differentiation by Suppressing the Development of Tolerogenic Dendritic Cells
It is demonstrated that MK was produced by inflammatory cells, in particular, CD4+ T cells under inflammatory conditions, and suggested that MK aggravates EAE by suppressing DCreg development, thereby impairing the Treg population. Expand
Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity.
The purpose of this paper is to give a general overview of the current literature on the significance of tDCs in tolerance maintenance to self and innocuous antigens, the most relevant alterations involved in the pathophysiology of ADs, the cellular and molecular mechanisms involved in their tolerogenic function and the current strategies used to exploit their toleranceogenic potential. Expand
Low-Dose Peptide Tolerance Therapy of Lupus Generates Plasmacytoid Dendritic Cells That Cause Expansion of Autoantigen-Specific Regulatory T Cells and Contraction of Inflammatory Th17 Cells12
Subnanomolar doses of an unaltered, naturally occurring nucleosomal histone peptide epitope, H471–94, when injected s.c. into lupus-prone mice, markedly prolong lifespan by generating CD4+25+ andExpand
Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis
Autoimmune diseases including multiple sclerosis (MS) are the result of an imbalanced immune tolerance network. Dendritic cells (DCs) are key players in both initiating immunity (immunogenic DCs) andExpand
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis
Clinical-grade tolDCs established from patients with RA exhibit a typical tolerogenic phenotype of reduced costimulatory molecules, low production of proinflammatory cytokines and impaired stimulation of autologous antigen-specific T cells, comparable to HC tol DCs. Expand
Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation
JQ1 impairs LPS-induced Mo-DC maturation by inhibiting STAT5 activity, thereby generating cells that can only weakly stimulate an adaptive-immune response, and could have beneficial effects in treating T cell–mediated inflammatory diseases. Expand
Stable antigen‐specific T‐cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients
Results suggest that myelin peptide‐loaded tolDCs may be a powerful tool for inducing myelin‐specific tolerance in RR‐MS patients. Expand
[Therapeutic effects of tolerogenic dendritic cells on ovalbumin allergic BALB/c mice].
It is demonstrated that caudal vein injection with tolerogenic AdTLA4Ig/Adα4β7-DC may be of potential research value in the treatment of food allergy by inducing immune tolerance in vivo. Expand